Regen BioPharma Inc (RGBP)

[PressAnyKey-]

Don’t forget RGBP hires that high polluting Patent Attorney to revive these:


The 12 Abandoned Patents list to be revived. also cancer vaccines[color=red][/color]

REGEN BIOPHARMA INC : Other Events (form 8-K)
05/07/2021 | 02:44pm EDT

Regen Biopharma, Inc. (the "Company") has begun the process of reviving patent applications of the Company filed with the United States Patent and Trademark Office ("USPTO") which have been classified as abandoned by the USPTO.

Legal services in connection with the abovementioned revival activities are being provided by Marc Baumgartner of Baumgartner Patent Law. Mr. Baumgartner has over 20 years of experience in the field of intellectual property law.

Application/PCT #Title of InventionStatus that may be revived...

13897735
ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS
Abandoned -- Failure To Respond To An Office Action

13957427
CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS
Abandoned -- Failure To Respond To An Office Action

13957431
CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS
Abandoned -- Failure To Respond To An Office Action

14854136
STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION
Abandoned -- Failure To Respond To An Office Action

14954902
IMMUNE MODULATION BY TLR ACTIVATION FOR TREATMENT OF FILOVIRUS INFECTIONS INCLUDING EBOLA
Abandoned -- Failure To Respond To An Office Action

15162370
ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES
Response To Non-Final Office Action Entered And Forwarded To Examiner

15250877
TREATMENT OF LIVER CANCER THROUGH EMBOLIZATION DEPOT DELIVERY OF BORIS GENE SILENCING AGENTS
Abandoned -- Failure To Respond To An Office Action

15364111
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY
Response To Non-Final Office Action Entered And Forwarded To Examiner

15431681
METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION
Abandonment For Failure To Correct Drawings/Oath/NonPub Request

15494358
UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS
Abandoned -- Failure To Pay Issue Fee

17010720
STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY
Application Dispatched From Preexam, Not Yet Docketed

62363588
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY
Provisional Application Expired

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163692235

RGBP Advisory board

Xiaojing Ma, Ph.D.
Senior Research Consultant

Dr. Ma is a Professor of Microbiology and Immunology at Weill Cornell Medical College. With over 100 scientific papers published and large research laboratory at a premier university, Dr. Ma brings extensive expertise to Regen as we develop our NR2F6 small molecules.

?Dr. Ma has been studying cytokines, particularly the IL-10 and IL-12 family of interleukins, for more than 20 years in many aspects of their regulation and immunobiology in various inflammatory autoimmune and tumor-immune models.

Dr. Ma’s group first identified a novel function of the Crohn’s disease-associated NOD2 mutation and uncovered the mechanisms by which IL-12 induces strong cell-mediated immune responses against various malignancies. He was also the first to identify a novel, non-chemokine activity of CCL5 in the generation and function of myeloid-derived suppressor cells and tumor-associated macrophages in the regulation of immune responses against breast cancer/mammary tumor.

https://www.regenbiopharmainc.com/management-team-and-scientific-advisory-board.html

National institute of health NR256

https://pubmed.ncbi.nlm.nih.gov/31937317/

mRNA-based cancer vaccines

Cancer vaccination involves the induction of tumor-specific T-cell responses potentially capable of tumor rejection by providing cancer antigens in the context of immunostimulation. Some cancer vaccines targeting surface exposed antigens additionally aim at inducing a tumor-specific B-cell response. Antigens are either tumor-associated self antigens (TAA), such as differentiation antigens, overexpressed antigens, cancer/testis antigens, or truly tumor-specific antigens (TSAs) not subject to immune tolerance, such as viral and mutated neoantigens. Various formats can be used for antigen delivery, including viral vectors, DNA, peptides, mRNA, or dendritic cells (DCs) pulsed with any of these.

mRNA has emerged as an attractive cancer vaccine format as it provides both antigen delivery and innate immune activation-mediated co-stimulation in a spatiotemporally aligned manner. mRNA vaccines encode the full or partial sequence of a TSA or TAA, and do not rely on prior identification of a patient’s human leukocyte antigen (HLA) haplotype or epitope prediction.

The feasibility of mRNA-based cancer vaccination was first demonstrated about 25?years ago [25, 26]. Since then, numerous preclinical and clinical studies explored mRNA for anti-cancer vaccination, either by loading it ex vivo on autologous DCs for adoptive transfer or by direct injection. A summary of all active, and completed or terminated phase II and III clinical trials using mRNA vaccines is provided in Table 1.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047518/

c'mon!!! millions of shares bought at .0210/11

still not moving🤦‍♂️ enough is enough $RGBP MM's pic.twitter.com/ij3kJQn8KC

— jtb3 (@jtb36) October 19, 2021

Use or lose


And this:

NR2F6 functions to repress expression of effector cytokines and acts as an intracellular immune checkpoint

Introduction
The immune system plays a pivotal role in limiting cancer growth (1), and insights into the mechanisms that govern how immune cells sense, interface with, and respond to cancer have led to the development of immunotherapeutic strategies that enhance anti-tumor immunity.

https://www.frontiersin.org/articles/10.3389/fimmu.2020.00057/full